{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:24:23Z","timestamp":1790065463766,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T00:00:00Z","timestamp":1462492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T00:00:00Z","timestamp":1462492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/cgt.2016.18","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T06:21:43Z","timestamp":1462515703000},"page":"178-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter\/enhancer sequences"],"prefix":"10.1038","volume":"23","author":[{"given":"S","family":"Chaurasiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Crosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Agopsowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Hitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,6]]},"reference":[{"key":"BFcgt201618_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2011.40.1919","volume":"30","author":"NJ Vogelzang","year":"2012","unstructured":"Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE et al. Clinical cancer advances 2011: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2012; 30: 88\u2013109.","journal-title":"J Clin Oncol"},{"key":"BFcgt201618_CR2","first-page":"614","volume":"22","author":"MJ Higgins","year":"2008","unstructured":"Higgins MJ, Wolff AC . Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) 2008; 22: 614\u2013623; discussion 623, 627-619.","journal-title":"Oncology (Williston Park)"},{"key":"BFcgt201618_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3816\/CBC.2008.n.025","volume":"8","author":"SE Jones","year":"2008","unstructured":"Jones SE . Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 2008; 8: 224\u2013233.","journal-title":"Clin Breast Cancer"},{"key":"BFcgt201618_CR4","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1172\/JCI60534","volume":"121","author":"K Polyak","year":"2011","unstructured":"Polyak K . Heterogeneity in breast cancer. J Clin Invest 2011; 121: 3786\u20133788.","journal-title":"J Clin Invest"},{"key":"BFcgt201618_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jnci\/89.1.21","volume":"89","author":"JA Roth","year":"1997","unstructured":"Roth JA, Cristiano RJ . Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21\u201339.","journal-title":"J Natl Cancer Inst"},{"key":"BFcgt201618_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2052-8426-2-27","volume":"2","author":"MH Amer","year":"2014","unstructured":"Amer MH . Gene therapy for cancer: present status and future perspective. Mol Cell Ther 2014; 2: 27.","journal-title":"Mol Cell Ther"},{"key":"BFcgt201618_CR7","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.4049\/jimmunol.1400034","volume":"193","author":"M Alvarez","year":"2014","unstructured":"Alvarez M, Bouchlaka MN, Sckisel GD, Sungur CM, Chen M, Murphy WJ . Increased antitumor effects using IL-2 with anti-TGF-beta reveals competition between mouse NK and CD8 T cells. J Immunol 2014; 193: 1709\u20131716.","journal-title":"J Immunol"},{"key":"BFcgt201618_CR8","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-11-3224","volume":"18","author":"AL Smith","year":"2012","unstructured":"Smith AL, Robin TP, Ford HL . Molecular pathways: targeting the TGF-beta pathway for cancer therapy. Clin Cancer Res 2012; 18: 4514\u20134521.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201618_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252\u2013264.","journal-title":"Nat Rev Cancer"},{"key":"BFcgt201618_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1252","volume":"4","author":"G Dranoff","year":"2004","unstructured":"Dranoff G . Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11\u201322.","journal-title":"Nat Rev Cancer"},{"key":"BFcgt201618_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cyto.2004.06.010","volume":"28","author":"SL Gaffen","year":"2004","unstructured":"Gaffen SL, Liu KD . Overview of interleukin-2 function, production and clinical applications. Cytokine 2004; 28: 109\u2013123.","journal-title":"Cytokine"},{"key":"BFcgt201618_CR12","doi-asserted-by":"publisher","first-page":"6342S","DOI":"10.1158\/1078-0432.CCR-040029","volume":"10","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Regan M, McDermott D . Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004; 10: 6342S\u20136346S.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201618_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/sonc.2002.33077","volume":"29","author":"MB Atkins","year":"2002","unstructured":"Atkins MB . Interleukin-2: clinical applications. Semin Oncol 2002; 29: 12\u201317.","journal-title":"Semin Oncol"},{"key":"BFcgt201618_CR14","first-page":"S55","volume":"6 Suppl 1","author":"RI Fisher","year":"2000","unstructured":"Fisher RI, Rosenberg SA, Fyfe G . Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 Suppl 1: S55\u2013S57.","journal-title":"Cancer J Sci Am"},{"key":"BFcgt201618_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0162-3109(97)00041-6","volume":"37","author":"R Baluna","year":"1997","unstructured":"Baluna R, Vitetta ES . Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997; 37: 117\u2013132.","journal-title":"Immunopharmacology"},{"key":"BFcgt201618_CR16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00262-008-0455-z","volume":"57","author":"W Den Otter","year":"2008","unstructured":"Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008; 57: 931\u2013950.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcgt201618_CR17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00262-002-0349-4","volume":"52","author":"CB Davis","year":"2003","unstructured":"Davis CB, Gillies SD . Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother 2003; 52: 297\u2013308.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcgt201618_CR18","doi-asserted-by":"publisher","first-page":"7826","DOI":"10.1073\/pnas.93.15.7826","volume":"93","author":"JC Becker","year":"1996","unstructured":"Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA . An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996; 93: 7826\u20137831.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201618_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/HAB-2000-10107","volume":"10","author":"ML Penichet","year":"2001","unstructured":"Penichet ML, Dela Cruz JS, Shin SU, Morrison SL . A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2\/neu expressing tumors. Hum Antibodies 2001; 10: 43\u201349.","journal-title":"Hum Antibodies"},{"key":"BFcgt201618_CR20","first-page":"1478","volume":"58","author":"J Lee","year":"1998","unstructured":"Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM . Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res 1998; 58: 1478\u20131485.","journal-title":"Cancer Res"},{"key":"BFcgt201618_CR21","first-page":"179","volume":"15","author":"VS Rao","year":"2006","unstructured":"Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J . Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep 2006; 15: 179\u2013185.","journal-title":"Oncol Rep"},{"key":"BFcgt201618_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2174\/1566523054546189","volume":"5","author":"H Sadeghi","year":"2005","unstructured":"Sadeghi H, Hitt MM . Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411\u2013427.","journal-title":"Curr Gene Ther"},{"key":"BFcgt201618_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.gt.3300508","volume":"4","author":"JL Bramson","year":"1997","unstructured":"Bramson JL, Hitt M, Gauldie J, Graham FL . Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Therapy 1997; 4: 1069\u20131076.","journal-title":"Gene Therapy"},{"key":"BFcgt201618_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2174\/1568009043332862","volume":"4","author":"PS Goedegebuure","year":"2004","unstructured":"Goedegebuure PS, Watson MA, Viehl CT, Fleming TP . Mammaglobin-based strategies for treatment of breast cancer. Curr Cancer Drug Targets 2004; 4: 531\u2013542.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFcgt201618_CR25","first-page":"3028","volume":"59","author":"MA Watson","year":"1999","unstructured":"Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999; 59: 3028\u20133031.","journal-title":"Cancer Res"},{"key":"BFcgt201618_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ymthe.2004.06.849","volume":"10","author":"CX Shi","year":"2004","unstructured":"Shi CX, Long MA, Liu L, Graham FL, Gauldie J, Hitt MM . The human SCGB2A2 (mammaglobin-1) promoter\/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells. Mol Ther 2004; 10: 758\u2013767.","journal-title":"Mol Ther"},{"key":"BFcgt201618_CR27","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/sj.gt.3300778","volume":"5","author":"DM Nettelbeck","year":"1998","unstructured":"Nettelbeck DM, Jerome V, Muller R . A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Therapy 1998; 5: 1656\u20131664.","journal-title":"Gene Therapy"},{"key":"BFcgt201618_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/jgm.867","volume":"8","author":"CX Shi","year":"2006","unstructured":"Shi CX, Graham FL, Hitt MM . A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter. J Gene Med 2006; 8: 442\u2013451.","journal-title":"J Gene Med"},{"key":"BFcgt201618_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nchembio814","volume":"2","author":"KS Putt","year":"2006","unstructured":"Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2006; 2: 543\u2013550.","journal-title":"Nat Chem Biol"},{"key":"BFcgt201618_CR30","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1021\/jm900722z","volume":"52","author":"QP Peterson","year":"2009","unstructured":"Peterson QP, Hsu DC, Goode DR, Novotny CJ, Totten RK, Hergenrother PJ . Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3. J Med Chem 2009; 52: 5721\u20135731.","journal-title":"J Med Chem"},{"key":"BFcgt201618_CR31","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1099\/0022-1317-78-7-1653","volume":"78","author":"CL Addison","year":"1997","unstructured":"Addison CL, Hitt M, Kunsken D, Graham FL . Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78: 1653\u20131661.","journal-title":"J Gen Virol"},{"key":"BFcgt201618_CR32","first-page":"88","volume":"2","author":"A Desilva","year":"2012","unstructured":"Desilva A, Wuest M, Wang M, Hummel J, Mossman K, Wuest F et al. Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT. Am J Nucl Med Mol Imaging 2012; 2: 88\u201398.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"BFcgt201618_CR33","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.1073\/pnas.91.19.8802","volume":"91","author":"AJ Bett","year":"1994","unstructured":"Bett AJ, Haddara W, Prevec L, Graham FL . An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802\u20138806.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201618_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1089\/hum.1998.9.5-707","volume":"9","author":"BM Putzer","year":"1998","unstructured":"Putzer BM, Bramson JL, Addison CL, Hitt M, Siegel PM, Muller WJ et al. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther 1998; 9: 707\u2013718.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201618_CR35","doi-asserted-by":"publisher","first-page":"8522","DOI":"10.1073\/pnas.92.18.8522","volume":"92","author":"CL Addison","year":"1995","unstructured":"Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL . Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522\u20138526.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201618_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/hmg\/8.1.137","volume":"8","author":"YS Cong","year":"1999","unstructured":"Cong YS, Wen J, Bacchetti S . The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999; 8: 137\u2013142.","journal-title":"Hum Mol Genet"},{"key":"BFcgt201618_CR37","volume-title":"Construction and Propagation of Human Adenovirus Vectors","author":"MM Hitt","year":"1994","unstructured":"Hitt MM, Bett AJ, Prevec L, Graham FL . Construction and Propagation of Human Adenovirus Vectors. Academic Press: New York, 1994."},{"key":"BFcgt201618_CR38","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1096\/fj.07-099234","volume":"22","author":"H Cen","year":"2008","unstructured":"Cen H, Mao F, Aronchik I, Fuentes RJ, Firestone GL . DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells. FASEB J 2008; 22: 2243\u20132252.","journal-title":"FASEB J"},{"key":"BFcgt201618_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1354\/vp.42-4-405","volume":"42","author":"JA Ramos-Vara","year":"2005","unstructured":"Ramos-Vara JA . Technical aspects of immunohistochemistry. Vet Pathol 2005; 42: 405\u2013426.","journal-title":"Vet Pathol"},{"key":"BFcgt201618_CR40","first-page":"5796","volume":"61","author":"T Komata","year":"2001","unstructured":"Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001; 61: 5796\u20135802.","journal-title":"Cancer Res"},{"key":"BFcgt201618_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/sj.mt.6300340","volume":"16","author":"S Wack","year":"2008","unstructured":"Wack S, Rejiba S, Parmentier C, Aprahamian M, Hajri A . Telomerase transcriptional targeting of inducible Bax\/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Mol Ther 2008; 16: 252\u2013260.","journal-title":"Mol Ther"},{"key":"BFcgt201618_CR42","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.gt.3300731","volume":"5","author":"CL Addison","year":"1998","unstructured":"Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL . Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy 1998; 5: 1400\u20131409.","journal-title":"Gene Therapy"},{"key":"BFcgt201618_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/CMAR.S33979","volume":"4","author":"BJ Coventry","year":"2012","unstructured":"Coventry BJ, Ashdown ML . The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res 2012; 4: 215\u2013221.","journal-title":"Cancer Manag Res"},{"key":"BFcgt201618_CR44","first-page":"507","volume":"56","author":"K Nakagawa","year":"1996","unstructured":"Nakagawa K, Miller FN, Sims DE, Lentsch AB, Miyazaki M, Edwards MJ . Mechanisms of interleukin-2-induced hepatic toxicity. Cancer Res 1996; 56: 507\u2013510.","journal-title":"Cancer Res"},{"key":"BFcgt201618_CR45","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/jnci\/95.10.741","volume":"95","author":"AL Epstein","year":"2003","unstructured":"Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA . Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003; 95: 741\u2013749.","journal-title":"J Natl Cancer Inst"},{"key":"BFcgt201618_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1479-5876-11-5","volume":"11","author":"J Laurent","year":"2013","unstructured":"Laurent J, Touvrey C, Gillessen S, Joffraud M, Vicari M, Bertrand C et al. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2\/anti-DNA fusion protein. J Transl Med 2013; 11: 5.","journal-title":"J Transl Med"},{"key":"BFcgt201618_CR47","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1073\/pnas.93.7.2702","volume":"93","author":"JC Becker","year":"1996","unstructured":"Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA . Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 1996; 93: 2702\u20132707.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201618_CR48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s002620050256","volume":"42","author":"JD Pancook","year":"1996","unstructured":"Pancook JD, Becker JC, Gillies SD, Reisfeld RA . Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother 1996; 42: 88\u201392.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcgt201618_CR49","doi-asserted-by":"publisher","first-page":"9626","DOI":"10.1073\/pnas.91.20.9626","volume":"91","author":"H Sabzevari","year":"1994","unstructured":"Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA . A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994; 91: 9626\u20139630.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201618_CR50","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s001099900038","volume":"77","author":"M Balzar","year":"1999","unstructured":"Balzar M, Winter MJ, de Boer CJ, Litvinov SV . The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) 1999; 77: 699\u2013712.","journal-title":"J Mol Med (Berl)"},{"key":"BFcgt201618_CR51","first-page":"4948","volume":"57","author":"R Xiang","year":"1997","unstructured":"Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 1997; 57: 4948\u20134955.","journal-title":"Cancer Res"},{"key":"BFcgt201618_CR52","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood.V91.5.1706","volume":"91","author":"HN Lode","year":"1998","unstructured":"Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA . Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998; 91: 1706\u20131715.","journal-title":"Blood"},{"key":"BFcgt201618_CR53","first-page":"307","volume":"1","author":"R Vile","year":"1994","unstructured":"Vile R, Miller N, Chernajovsky Y, Hart I . A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Therapy 1994; 1: 307\u2013316.","journal-title":"Gene Therapy"},{"key":"BFcgt201618_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s004320050245","volume":"125","author":"P He","year":"1999","unstructured":"He P, Tang ZY, Liu BB, Ye SL, Liu YK . The targeted expression of the human interleukin-2\/interferon alpha2b fused gene in alpha-fetoprotein-expressing hepatocellular carcinoma cells. J Cancer Res Clin Oncol 1999; 125: 77\u201382.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFcgt201618_CR55","first-page":"11","volume":"3","author":"EM Toloza","year":"1996","unstructured":"Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996; 3: 11\u201317.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201618_CR56","first-page":"2193","volume":"48","author":"J Vaage","year":"1988","unstructured":"Vaage J . Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities. Cancer Res 1988; 48: 2193\u20132197.","journal-title":"Cancer Res"},{"key":"BFcgt201618_CR57","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.1158\/0008-5472.CAN-10-0766","volume":"70","author":"QP Peterson","year":"2010","unstructured":"Peterson QP, Hsu DC, Novotny CJ, West DC, Kim D, Schmit JM et al. Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound. Cancer Res 2010; 70: 7232\u20137241.","journal-title":"Cancer Res"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201618.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201618","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201618.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T08:05:49Z","timestamp":1647936349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFcgt201618"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2016.18","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,6]]},"assertion":[{"value":"10 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}